Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).
Douglas G McNeelJens C EickhoffEllen WargowskiLaura E JohnsonChristos E KyriakopoulosHamid EmamekhooJoshua M LangMary Jane BrennanGlenn LiuPublished in: Journal for immunotherapy of cancer (2022)
NCT02499835.
Keyphrases